TPST Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Tempest Therapeutics Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerTPST

Market Cap22.4M

Cash RunwayRunway < 6 months

Next Catalyst2027-07

Public Research Snapshot

Tempest Therapeutics Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for Pentosan Polysulfate Sodium twice weekly in Osteoarthritis, Knee (Phase 3).

Pipeline

Asset	Indication	Modality	Stage	Public Note
Atezolizumab	Advanced Liver Cancers	n/a	Phase 1 \| Phase 2	Public pipeline row
Pentosan Polysulfate Sodium twice weekly	Osteoarthritis, Knee	n/a	Phase 3	Public pipeline row
Eloralintide	Sleep Apnea, Obstructive \| Obesity \| Overweight	n/a	Phase 3	Public pipeline row

Catalyst Preview

Catalyst	Timing	Asset	Confidence
Clinical Trial Completion	2027-07	Pentosan Polysulfate Sodium twice weekly	Low
Clinical Trial Completion	2027-07-30	Atezolizumab	Low
Clinical Trial Completion	2028-03	Eloralintide	Low

Cash Runway Preview

Estimated cash runway: Runway < 6 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT06917404	Phase 3	RECRUITING	466	2027-07
NCT04524871	Phase 1 \| Phase 2	RECRUITING	518	2027-07-30
NCT07369011	Phase 3	RECRUITING	800	2028-03

Scientific Context

literature_publication | Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study.
literature_publication | Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial.
literature_publication | HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial results.
literature_publication | Fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab: Tumor-specific expansion cohorts in advanced malignancies.
literature_publication | Domvanalimab combined with zimberelimab as first-line treatment in patients with PD-L1-high, advanced non-small cell lung cancer: Results from the randomized phase 2 ARC-10 study, Part1.

Want the full TPST research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.